Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Jun 2

PMID 34073229

Citations 11

Authors

Sara Bernardo-Castro

Ines Albino

Angela Maria Barrera-Sandoval

Francesca Tomatis

Joao Andre Sousa

Emanuel Martins

Susana Simoes

Miguel M Lino

Lino Ferreira

Joao Sargento-Freitas

Affiliations

Soon will be listed here.

Abstract

Stroke represents the second leading cause of mortality and morbidity worldwide. Ischemic strokes are the most prevalent type of stroke, and they are characterized by a series of pathological events prompted by an arterial occlusion that leads to a heterogeneous pathophysiological response through different hemodynamic phases, namely the hyperacute, acute, subacute, and chronic phases. Stroke treatment is highly reliant on recanalization therapies, which are limited to only a subset of patients due to their narrow therapeutic window; hence, there is a huge need for new stroke treatments. Nonetheless, the vast majority of promising treatments are not effective in the clinical setting due to their inability to cross the blood-brain barrier and reach the brain. In this context, nanotechnology-based approaches such as nanoparticle drug delivery emerge as the most promising option. In this review, we will discuss the current status of nanotechnology in the setting of stroke, focusing on the diverse available nanoparticle approaches targeted to the different pathological and physiological repair mechanisms involved in each of the stroke phases.

Citing Articles

Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy.

Sukubo N, Bigini P, Morelli A Beilstein J Nanotechnol. 2025; 16:97-118.

PMID: 39902342 PMC: 11789677. DOI: 10.3762/bjnano.16.10.

Role of Nanotechnology in Ischemic Stroke: Advancements in Targeted Therapies and Diagnostics for Enhanced Clinical Outcomes.

Yadav V, Gupta R, Assiri A, Uddin J, Ishaqui A, Kumar P J Funct Biomater. 2025; 16(1).

PMID: 39852564 PMC: 11766075. DOI: 10.3390/jfb16010008.

In Vitro and in vivo characterization of nasal pH-Responsive in-situ hydrogel of Candesartan-loaded invasomes as a potential stroke treatment.

El-Housiny S, Fouad A, El-Bakry R, Zaki R, Afzal O, Abo El-Ela F Drug Deliv Transl Res. 2024; .

PMID: 39259459 DOI: 10.1007/s13346-024-01700-z.

Nanomaterial-Based Strategies for Attenuating T-Cell-Mediated Immunodepression in Stroke Patients: Advancing Research Perspectives.

Wang Y, Liu C, Ren Y, Song J, Fan K, Gao L Int J Nanomedicine. 2024; 19:5793-5812.

PMID: 38882535 PMC: 11180442. DOI: 10.2147/IJN.S456632.

Functional candesartan loaded lipid nanoparticles for the control of diabetes-associated stroke: In vitro in vivo .

Mahmoud D, Ali M, Aldosari B, Zaki R, Afzal O, Tulbah A Int J Pharm X. 2024; 7:100227.

PMID: 38260917 PMC: 10801309. DOI: 10.1016/j.ijpx.2023.100227.

References

Kim J, Ryu J, Schellingerhout D, Sun I, Lee S, Jeon S . Direct Imaging of Cerebral Thromboemboli Using Computed Tomography and Fibrin-targeted Gold Nanoparticles. Theranostics. 2015; 5(10):1098-114. PMC: 4508499. DOI: 10.7150/thno.11679. View

Zhang Z, Buller B, Chopp M . Exosomes - beyond stem cells for restorative therapy in stroke and neurological injury. Nat Rev Neurol. 2019; 15(4):193-203. DOI: 10.1038/s41582-018-0126-4. View

Tapeinos C, Battaglini M, Ciofani G . Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017; 264:306-332. PMC: 6701993. DOI: 10.1016/j.jconrel.2017.08.033. View

Huang Y, Cambre M, Lee H . The Toxicity of Nanoparticles Depends on Multiple Molecular and Physicochemical Mechanisms. Int J Mol Sci. 2017; 18(12). PMC: 5751303. DOI: 10.3390/ijms18122702. View

Papanagiotou P, Ntaios G . Endovascular Thrombectomy in Acute Ischemic Stroke. Circ Cardiovasc Interv. 2018; 11(1):e005362. DOI: 10.1161/CIRCINTERVENTIONS.117.005362. View

Xin H, Wang F, Li Y, Lu Q, Cheung W, Zhang Y . Secondary Release of Exosomes From Astrocytes Contributes to the Increase in Neural Plasticity and Improvement of Functional Recovery After Stroke in Rats Treated With Exosomes Harvested From MicroRNA 133b-Overexpressing Multipotent Mesenchymal.... Cell Transplant. 2016; 26(2):243-257. PMC: 5303172. DOI: 10.3727/096368916X693031. View

Santos S, Xavier M, M Leite D, Moreira D, Custodio B, Torrado M . PAMAM dendrimers: blood-brain barrier transport and neuronal uptake after focal brain ischemia. J Control Release. 2018; 291:65-79. DOI: 10.1016/j.jconrel.2018.10.006. View

Allen N, Kaltenbach L, Goldstein L, Olson D, Smith E, Peterson E . Regional variation in recommended treatments for ischemic stroke and TIA: Get with the Guidelines--Stroke 2003-2010. Stroke. 2012; 43(7):1858-64. DOI: 10.1161/STROKEAHA.112.652305. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Bamford J, Sandercock P, Dennis M, Burn J, Warlow C . Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991; 337(8756):1521-6. DOI: 10.1016/0140-6736(91)93206-o. View

11.

Carmichael S . The 3 Rs of Stroke Biology: Radial, Relayed, and Regenerative. Neurotherapeutics. 2015; 13(2):348-59. PMC: 4824028. DOI: 10.1007/s13311-015-0408-0. View

12.

Bernardo-Castro S, Sousa J, Bras A, Cecilia C, Rodrigues B, Almendra L . Pathophysiology of Blood-Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery. Front Neurol. 2020; 11:594672. PMC: 7756029. DOI: 10.3389/fneur.2020.594672. View

13.

Petty K, Lemkuil B, Gierl B . Acute Ischemic Stroke. Anesthesiol Clin. 2021; 39(1):113-125. DOI: 10.1016/j.anclin.2020.11.002. View

14.

Deng L, Zhang F, Wu Y, Luo J, Mao X, Long L . RGD-Modified Nanocarrier-Mediated Targeted Delivery of Plasmid DNA to Cerebrovascular Endothelial Cells for Ischemic Stroke Treatment. ACS Biomater Sci Eng. 2021; 5(11):6254-6264. DOI: 10.1021/acsbiomaterials.9b01362. View

15.

Bai Y, Gao X, Wang Y, Peng X, Chang D, Zheng S . Image-guided pro-angiogenic therapy in diabetic stroke mouse models using a multi-modal nanoprobe. Theranostics. 2014; 4(8):787-97. PMC: 4063977. DOI: 10.7150/thno.9525. View

16.

Zenych A, Fournier L, Chauvierre C . Nanomedicine progress in thrombolytic therapy. Biomaterials. 2020; 258:120297. DOI: 10.1016/j.biomaterials.2020.120297. View

17.

Xin H, Li Y, Cui Y, Yang J, Zhang Z, Chopp M . Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab. 2013; 33(11):1711-5. PMC: 3824189. DOI: 10.1038/jcbfm.2013.152. View

18.

Yang Q, Huang Q, Hu Z, Tang X . Potential Neuroprotective Treatment of Stroke: Targeting Excitotoxicity, Oxidative Stress, and Inflammation. Front Neurosci. 2019; 13:1036. PMC: 6777147. DOI: 10.3389/fnins.2019.01036. View

19.

Huang Y, Wu J, Su T, Zhang S, Lin X . Fasudil, a Rho-Kinase Inhibitor, Exerts Cardioprotective Function in Animal Models of Myocardial Ischemia/Reperfusion Injury: A Meta-Analysis and Review of Preclinical Evidence and Possible Mechanisms. Front Pharmacol. 2018; 9:1083. PMC: 6174418. DOI: 10.3389/fphar.2018.01083. View

20.

Hu Y, Gao J . Potential neurotoxicity of nanoparticles. Int J Pharm. 2010; 394(1-2):115-21. DOI: 10.1016/j.ijpharm.2010.04.026. View